Ridgeback Capital Investments Buys Entire Portfolio in Q2 2026
As of June 30, 2026, Ridgeback Capital Investments L.P. held a fully concentrated portfolio with Replimune Group Inc. (REPL).
Investor Position Changes
This quarter's filing for Ridgeback Capital Investments L.P. reveals a significant shift in its portfolio holdings. The data shows that the investor has made changes resulting in a fully concentrated position, with all assets allocated to one stock.
New Position: Replimune Group Inc. (REPL)
The primary change observed is the establishment of a new major holding. Replimune Group Inc. (REPL), operating in the Healthcare sector, now represents 100% of the portfolio's value according to the most recent data available for this quarter.
The investor acquired a substantial position in Replimune during Q2. The total shares held increased by 7,310,656 from the previous period, representing a change percentage of 100%. This indicates that either no positions existed before or all prior holdings were completely liquidated to fund this new investment.
No Sales Observed
According to the disclosed data, there were no sales activities reported by Ridgeback Capital Investments L.P. during this quarter. The change in shares for Replimune was purely an increase with a 100% allocation percentage, suggesting no divestment occurred.
The portfolio's holdings count remained at one throughout the period, indicating that Ridgeback Capital did not diversify or add any other stocks to its investment strategy this quarter.
Sector Focus Remains Healthcare
The filing confirms that the investor's entire portfolio allocation is within the Healthcare sector, specifically concentrated in Replimune Group Inc. (REPL). This reinforces a focused investment approach centered on opportunities within this particular industry segment.
The top holdings data aligns perfectly with the changed holdings information, showing only one stock and no changes in allocation percentage. The indicators reflect that Ridgeback Capital has a fully concentrated portfolio this quarter.
No Large Sells Disclosed
The filing does not disclose any large sell activities by Ridgeback Capital Investments L.P. during the quarter. The 'has_large_sells' indicator is set to false, and there are no significant sell symbols listed in the data.
In summary, Ridgeback Capital's portfolio activity for Q2 2026 appears characterized by a complete shift towards Replimune Group Inc., resulting in full concentration on one stock within the Healthcare sector. Investors should monitor this concentrated position closely.